WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Endocyte Inc., a company developing targeted small-molecule drug conjugates, will present results of an interim analysis from a randomized phase II clinical trial in women with platinum-resistant ovarian cancer on Sunday (June 6) during the 46th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
